Serum Free Production of Three-dimensional Human Hepatospheres from Pluripotent Stem Cells
July 20th, 2019
9.8K views
This protocol describes an approach to produce hepatospheres from human pluripotent stem cells using a defined culture system and cell self-assembly. This protocol is reproducible in a number of cell lines, cost effective and allows the production of stable human hepatospheres for biomedical application.
Overview
This protocol outlines a method for generating hepatospheres from human pluripotent stem cells using a defined culture system. The technique emphasizes cell self-assembly and is reproducible across various cell lines.
Key Study Components
Area of Science
- Stem Cell Biology
- Regenerative Medicine
- 3D Cell Culture
Background
- Hepatospheres are 3D structures that mimic liver tissue.
- Human pluripotent stem cells can differentiate into hepatocyte-like cells.
- Controlling the size of hepatospheres is crucial for functionality.
- This method aims to produce stable hepatospheres for biomedical applications.
Purpose of Study
- To develop a cost-effective protocol for hepatosphere production.
- To enhance the reproducibility of hepatosphere formation.
- To facilitate the use of hepatospheres in disease modeling and drug screening.
Methods Used
- Preparation of agarose molds for cell culture.
- Cell dissociation and counting using trypan blue staining.
- Seeding cells into agarose micro wells and incubating under controlled conditions.
- Inducing differentiation into hepatocyte-like cells through medium changes.
Main Results
- Hepatospheres formed display functional characteristics similar to primary hepatocytes.
- Secretion of liver-specific proteins such as Albumin and alpha-fetoprotein was observed.
- 3D spheres maintained functionality over extended culture periods.
- Methodology allows for the generation of hepatospheres suitable for various applications.
Conclusions
- This protocol enables the production of stable and functional hepatospheres.
- It has potential applications in drug screening and disease modeling.
- Future studies may expand this technology to other tissue types.
Frequently Asked Questions
What are hepatospheres?
Hepatospheres are 3D structures derived from stem cells that mimic liver tissue.
How are hepatospheres produced?
They are produced through a defined culture system that promotes cell self-assembly.
What is the significance of using human pluripotent stem cells?
They can differentiate into hepatocyte-like cells, providing a relevant model for liver studies.
How long can hepatospheres maintain functionality?
Hepatospheres can remain functional for over a year in vitro.
What applications do hepatospheres have?
They are useful in disease modeling and drug screening.
What precautions should be taken during the protocol?
Gently pipetting the hepatospheres is crucial to avoid damaging them.
Executive Industry Relevance
This method enables scalable production of functional human hepatospheres from pluripotent stem cells, addressing the need for reliable in vitro liver models in early drug discovery. By controlling sphere size and preventing necrotic cores, it improves phenotypic stability and predictive value for hepatotoxicity and metabolism studies. The approach supports translational continuity from target validation to preclinical screening, reducing biological de-risking gaps in liver-targeted programs.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of hepatic differentiation pathways and target engagement in a human-relevant 3D system.
- Operational Value: Provides a renewable source of hepatocyte-like cells for consistent target validation assays.
Screening & Assay Development
- Scientific Value: Generates spheroids with demonstrable CYP450 activity and liver protein secretion for functional readouts.
- Operational Value: Uses agarose microwell technology to standardize sphere size and improve reproducibility across screening campaigns.
- Strategic Value: Supports long-term culture stability (>1 year), enabling chronic dosing and repeated compound evaluation.
Translational & Preclinical Research
- Scientific Value: Models human liver tissue architecture with hepatocyte-like outer layers and mesenchymal cores for mechanistic de-risking.
- Operational Value: Facilitates transfer to poly-HEMA coated wells for maturation and long-term maintenance under defined conditions.
- Predictive Value: Secretion of albumin and alpha-fetoprotein provides quantifiable biomarkers for lot-to-lot consistency and batch release.
Pipeline & Workflow Integration
The method fits within the discovery continuum from stem cell differentiation to functional assay readiness, supporting lead identification and preclinical efficacy testing.
- Discovery Biology: Enables controlled endoderm to hepatoblast to hepatocyte differentiation for pathway and target validation.
- Screening: Delivers size-controlled hepatospheres suitable for high-content imaging and multi-parametric readouts.
- Analytics: Provides quantitative outputs including CYP450 activity, albumin secretion, and alpha-fetoprotein levels for comparative compound profiling.
- Translational Research: Maintains stable phenotype and function over extended culture, supporting chronic toxicity and disease modeling studies.
- Enterprise Reuse: Defined, serum-free protocol allows technology transfer across sites and cell lines for platform standardization.
Operational & Enterprise Impact
- Scientific Value: Enhances predictive confidence by modeling human liver zonation and reducing reliance on primary hepatocytes or animal models.
- Operational Value: Eliminates serum variability and uses defined media for lot-to-lot consistency and GMP-adaptable production.
- Strategic Value: Enables early identification of hepatotoxic liabilities, improving go/no-go decisions and reducing late-stage attrition.
- Portfolio Impact: Supports risk-adjusted prioritization of liver-targeted candidates through reliable, scalable in vitro phenotyping.
Implementation Considerations
- Requires expertise in stem cell culture, 3D spheroid formation, and hepatocyte differentiation protocols.
- Depends on agarose microwell fabrication and poly-HEMA coating infrastructure for sphere generation and transfer.
- Necessitates standardized cell seeding densities and ROCK inhibitor use to ensure viability and prevent anoikis.
- Requires adaptation of medium formulations when extending to other endodermal or mesenchymal tissues.
- Limited by the need for careful pipetting during transfer to avoid shear-induced damage to fragile hepatospheres.
Biopharma FAQs
Why control hepatosphere size in 3D liver models?
Controlling size prevents necrotic and apoptotic cores, maintaining hepatocyte function and phenotype stability over long-term culture.
How does agarose microwell technology improve hepatosphere reproducibility?
Agarose microwells define cell seeding density, ensuring uniform sphere formation and reducing variability in downstream functional assays.
What quantitative measurements indicate hepatosphere functionality?
Functionality is demonstrated by CYP450 activity levels and secretion of liver-specific proteins such as albumin and alpha-fetoprotein.
Why are replication requirements important for hepatosphere-based assays?
Replication ensures consistent spheroid quality and reliable data across experiments, supporting cross-functional decision-making in drug discovery.
What statistical analysis is needed before implementing hepatosphere models in screening?
Analysis of functional readouts like enzyme activity and protein secretion is required to establish assay windows and compound effect thresholds.
